Skip to main content
SpringerLink
Log in

Cognitive and Behavioral Neurology

  • Chapter
  • First Online:
Neurology

  • 3025 Accesses

Abstract

The number of patients with neurodegenerative diseases, such as Alzheimer’s disease, dementia with Lewy bodies, frontotemporal and vascular dementia is quickly rising with the aging population. Neurologist and other health care providers will be increasingly confronted with the diagnosis and management of these disorders. In this chapter, the authors present answers to questions frequently raised by patients and caregivers during the evaluation and treatment of these cognitive disorders. Evidence for current diagnostic and treatment approaches for each of these neurodegenerative diseases are reviewed. Each section is enhanced with bottom lines or take-home message and summaries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51:728–33.

    PubMed  CAS  Google Scholar 

  2. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59:1737–46.

    PubMed  Google Scholar 

  3. Edland SD, Rocca WA, Petersen RC, Cha RH, Kokmen E. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn. Arch Neurol. 2002;59:1589–93.

    PubMed  Google Scholar 

  4. Mortimer JA, Snowdon DA, Markesbery WR. Head circumference, education and risk of dementia: findings from the Nun Study. J Clin Exp Neuropsychol. 2003;25:671–9.

    PubMed  Google Scholar 

  5. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125–32.

    PubMed  CAS  Google Scholar 

  6. Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology. 2000;55:198–204.

    PubMed  CAS  Google Scholar 

  7. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S4–9.

    PubMed  CAS  Google Scholar 

  8. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 1999;53:321–31.

    PubMed  CAS  Google Scholar 

  9. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55:964–8.

    PubMed  CAS  Google Scholar 

  10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.

    PubMed  CAS  Google Scholar 

  11. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer’s disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry. 1999;174:45–50.

    PubMed  CAS  Google Scholar 

  12. Kazee AM, Eskin TA, Lapham LW, Gabriel KR, McDaniel KD, Hamill RW. Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord. 1993;7:152–64.

    PubMed  CAS  Google Scholar 

  13. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66:184–8.

    PubMed  CAS  Google Scholar 

  14. Nagy Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EM, et al. Accuracy of clinical operational diagnostic criteria for Alzheimer’s disease in relation to different pathological diagnostic protocols. Dement Geriatr Cogn Disord. 1998;9:219–26.

    PubMed  CAS  Google Scholar 

  15. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res. 2009;43:411–31.

    PubMed  Google Scholar 

  16. Narasimhalu K, Lee J, Auchus AP, Chen CP. Improving detection of dementia in Asian patients with low education: combining the Mini-Mental State Examination and the Informant Questionnaire on Cognitive Decline in the Elderly. Dement Geriatr Cogn Disord. 2008;25:17–22.

    PubMed  Google Scholar 

  17. Luis CA, Keegan AP, Mullan M. Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US. Int J Geriatr Psychiatry. 2009;24:197–201.

    PubMed  Google Scholar 

  18. Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007;52:329–32.

    PubMed  Google Scholar 

  19. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–53.

    PubMed  CAS  Google Scholar 

  20. Welsh K, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer’s disease using CERAD neuropsychological measures. Arch Neurol. 1991;48:278–81.

    PubMed  CAS  Google Scholar 

  21. Cahn DA, Salmon DP, Butters N, Wiederholt WC, Corey-Bloom J, Edelstein SL, et al. Detection of dementia of the Alzheimer type in a population-based sample: neuropsychological test performance. J Int Neuropsychol Soc. 1995;1:252–60.

    PubMed  CAS  Google Scholar 

  22. Wahlund LO, Julin P, Johansson SE, Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry. 2000;69:630–5.

    PubMed  CAS  Google Scholar 

  23. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871–7.

    PubMed  CAS  Google Scholar 

  24. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT. Alzheimer disease: operating characteristics of PET–a meta-analysis. Radiology. 2004;231:73–80.

    PubMed  Google Scholar 

  25. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry. 2004;12:554–70.

    PubMed  Google Scholar 

  26. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.

    PubMed  CAS  Google Scholar 

  27. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718–25.

    PubMed  CAS  Google Scholar 

  28. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228–34.

    PubMed  CAS  Google Scholar 

  29. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64:1294–7.

    PubMed  CAS  Google Scholar 

  30. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med. 1998;338:506–11.

    PubMed  CAS  Google Scholar 

  31. Hentschel F, Kreis M, Damian M, Krumm B, Frolich L. The clinical utility of structural neuroimaging with MRI for diagnosis and differential diagnosis of dementia: a memory clinic study. Int J Geriatr Psychiatry. 2005;20:645–50.

    PubMed  CAS  Google Scholar 

  32. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007;64:108–15.

    PubMed  Google Scholar 

  33. Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2006;77:1219–22.

    PubMed  CAS  Google Scholar 

  34. Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology. 2004;63:94–100.

    PubMed  Google Scholar 

  35. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509–17.

    PubMed  Google Scholar 

  36. Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, Nordberg A, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008;35:100–6.

    PubMed  Google Scholar 

  37. Rabinovici GD, Furst AJ, O’Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11 C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68: 1205–12.

    PubMed  CAS  Google Scholar 

  38. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373–9.

    PubMed  CAS  Google Scholar 

  39. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14:e1–26.

    PubMed  CAS  Google Scholar 

  40. Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, et al. Estimation of the genetic contribution of presenilin-1 and −2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998;7:43–51.

    PubMed  CAS  Google Scholar 

  41. Kamimura K, Tanahashi H, Yamanaka H, Takahashi K, Asada T, Tabira T. Familial Alzheimer’s disease genes in Japanese. J Neurol Sci. 1998;160:76–81.

    PubMed  CAS  Google Scholar 

  42. Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer’s disease: mutation frequency in 31 families. Neurology. 2003;60:235–9.

    PubMed  CAS  Google Scholar 

  43. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006:CD005593.

    Google Scholar 

  44. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006:CD003154.

    Google Scholar 

  45. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006:CD001190.

    Google Scholar 

  46. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357:1382–92.

    PubMed  CAS  Google Scholar 

  47. Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006:CD001747.

    Google Scholar 

  48. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2000:CD001191.

    Google Scholar 

  49. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83–9.

    PubMed  CAS  Google Scholar 

  50. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13:97–107.

    PubMed  CAS  Google Scholar 

  51. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42:32–8.

    PubMed  Google Scholar 

  52. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22:209–21.

    PubMed  CAS  Google Scholar 

  53. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RAD, Wolk DA, et al. Memantine augments the effects of cholinesterase inhibition in the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2009. doi:10.1136/jnnp. 2008.158964.

  54. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57–63.

    PubMed  CAS  Google Scholar 

  55. Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006;20:263–8.

    PubMed  CAS  Google Scholar 

  56. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2009:CD003476.

    Google Scholar 

  57. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–43.

    PubMed  CAS  Google Scholar 

  58. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8:151–7.

    PubMed  CAS  Google Scholar 

  59. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844–54.

    PubMed  Google Scholar 

  60. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–38.

    PubMed  CAS  Google Scholar 

  61. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819–26.

    PubMed  CAS  Google Scholar 

  62. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62:66–71.

    PubMed  CAS  Google Scholar 

  63. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;23:8–21.

    PubMed  CAS  Google Scholar 

  64. de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS ONE. 2008;3:e1475.

    PubMed  Google Scholar 

  65. Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J. Aspirin in Alzheimer’s disease (AD2000): a randomised open-label trial. Lancet Neurol. 2008;7:41–9.

    PubMed  CAS  Google Scholar 

  66. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008:CD002854.

    Google Scholar 

  67. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997;336:1216–22.

    PubMed  CAS  Google Scholar 

  68. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–88.

    PubMed  CAS  Google Scholar 

  69. Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.

    PubMed  CAS  Google Scholar 

  70. Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology. 2008;70:2219–25.

    PubMed  CAS  Google Scholar 

  71. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69:878–85.

    PubMed  CAS  Google Scholar 

  72. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80:13–7.

    PubMed  CAS  Google Scholar 

  73. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer’s disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23:194–201.

    PubMed  Google Scholar 

  74. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62: 753–7.

    PubMed  Google Scholar 

  75. Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST. Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol. 2005;62:779–84.

    PubMed  Google Scholar 

  76. Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59:1764–7.

    PubMed  Google Scholar 

  77. Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140:501–9.

    PubMed  Google Scholar 

  78. Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y. Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology. 2008;71:1489–95.

    PubMed  CAS  Google Scholar 

  79. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol. 2001;154:642–8.

    PubMed  CAS  Google Scholar 

  80. Mercy L, Hodges JR, Dawson K, Barker RA, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology. 2008;71:1496–9.

    PubMed  CAS  Google Scholar 

  81. Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology. 2004;62:506–8.

    PubMed  CAS  Google Scholar 

  82. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615–21.

    PubMed  CAS  Google Scholar 

  83. Rosso SM, Donker Kaat L, Baks T, Joosse M, de Koning I, Pijnenburg Y, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain. 2003;126:2016–22.

    PubMed  Google Scholar 

  84. Grasbeck A, Horstmann V, Nilsson K, Sjobeck M, Sjostrom H, Gustafson L. Dementia in first-degree relatives of patients with frontotemporal dementia. A family history study. Dement Geriatr Cogn Disord. 2005;19:145–53.

    PubMed  CAS  Google Scholar 

  85. Stevens M, van Duijn CM, Kamphorst W, de Knijff P, Heutink P, van Gool WA, et al. Familial aggregation in frontotemporal dementia. Neurology. 1998;50:1541–5.

    PubMed  CAS  Google Scholar 

  86. Goldman JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65:1817–9.

    PubMed  CAS  Google Scholar 

  87. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.

    PubMed  CAS  Google Scholar 

  88. Mendez MF, Shapira JS, McMurtray A, Licht E, Miller BL. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol. 2007;64:830–5.

    PubMed  Google Scholar 

  89. Blair M, Kertesz A, Davis-Faroque N, Hsiung GY, Black SE, Bouchard RW, et al. Behavioural measures in frontotemporal lobar dementia and other dementias: the utility of the frontal behavioural inventory and the neuropsychiatric inventory in a national cohort study. Dement Geriatr Cogn Disord. 2007;23:406–15.

    PubMed  CAS  Google Scholar 

  90. Milan G, Lamenza F, Iavarone A, Galeone F, Lore E, de Falco C, et al. Frontal Behavioural Inventory in the differential diagnosis of dementia. Acta Neurol Scand. 2008;117:260–5.

    PubMed  CAS  Google Scholar 

  91. Likeman M, Anderson VM, Stevens JM, Waldman AD, Godbolt AK, Frost C, et al. Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. Arch Neurol. 2005;62:1410–5.

    PubMed  Google Scholar 

  92. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130:2616–35.

    PubMed  Google Scholar 

  93. McNeill R, Sare GM, Manoharan M, Testa HJ, Mann DMA, Neary D, et al. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2007;78:350–5.

    PubMed  CAS  Google Scholar 

  94. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70:1827–35.

    PubMed  CAS  Google Scholar 

  95. Kapaki E, Paraskevas GP, Papageorgious SG, Bonakis A, Kalfakis N, Zalonis I, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2008;22:47–53.

    PubMed  CAS  Google Scholar 

  96. Hutchinson AD, Mathias JL. Neuropsychological deficits in frontotemporal dementia and Alzheimer’s disease: a meta-analytic review. J Neurol Neurosurg Psychiatry. 2007;78:917–28.

    PubMed  CAS  Google Scholar 

  97. Perry RJ, Hodges JR. Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer’s disease. Neurology. 2000;54:2277–84.

    PubMed  CAS  Google Scholar 

  98. Houlden H, Baker M, Adamson J, Grover A, Waring S, Dickson D, et al. Frequency of tau mutations in three series of non-Alzheimer’s degenerative dementia. Ann Neurol. 1999;46:243–8.

    PubMed  CAS  Google Scholar 

  99. Benussi L, Ghidoni R, Pegoiani E, Moretti DV, Zanetti O, Binetti G. Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiol Dis. 2009;33:379–85.

    PubMed  CAS  Google Scholar 

  100. Kruger J, Kaivorinne AL, Udd B, Majamaa K, Remes AM. Low prevalence of progranulin mutations in Finnish patients with frontotemporal lobar degeneration. Eur J Neurol. 2009;16:27–30.

    PubMed  CAS  Google Scholar 

  101. Pickering-Brown SM, Rollinson S, Du Plessis D, Morrison KE, Varma A, Richardson AM, et al. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain. 2008;131:721–31.

    PubMed  Google Scholar 

  102. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172:400–8.

    CAS  Google Scholar 

  103. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13–9.

    PubMed  CAS  Google Scholar 

  104. Ikeda M, Shigenobu K, Fukuhara R, Hokoishi K, Maki N, Nebu A, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004;17:117–21.

    PubMed  CAS  Google Scholar 

  105. Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742–5.

    PubMed  Google Scholar 

  106. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212–6.

    PubMed  CAS  Google Scholar 

  107. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355–9.

    PubMed  CAS  Google Scholar 

  108. Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178–85.

    PubMed  CAS  Google Scholar 

  109. Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84–7.

    PubMed  Google Scholar 

  110. Rahman S, Robbins TW, Hodges JR, Mehta MA, Nestor PJ, Clark L, et al. Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651–8.

    PubMed  CAS  Google Scholar 

  111. Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology. 2003;61:349–54.

    PubMed  CAS  Google Scholar 

  112. Roberson ED, Hesse JH, Rose KD, Slama H, Johnson JK, Yaffe K, et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology. 2005;65:719–25.

    PubMed  CAS  Google Scholar 

  113. Bergeron C, Pollanen M. Lewy bodies in Alzheimer disease–one or two diseases? Alzheimer Dis Assoc Disord. 1989;3:197–204.

    PubMed  CAS  Google Scholar 

  114. Gibb WR, Lees AJ. Prevalence of Lewy bodies in Alzheimer’s disease. Ann Neurol. 1989;26:691–3.

    PubMed  CAS  Google Scholar 

  115. Iseki E. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson’s disease or Alzheimer’s disease. Neuropathology. 2004;24:72–8.

    PubMed  Google Scholar 

  116. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9:417–23.

    PubMed  Google Scholar 

  117. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–24.

    PubMed  CAS  Google Scholar 

  118. Jhoo JH, Kim KW, Huh Y, Lee SB, Park JH, Lee JJ, et al. Prevalence of dementia and its subtypes in an elderly urban korean population: results from the Korean Longitudinal Study on Health And Aging (KLoSHA). Dement Geriatr Cogn Disord. 2008;26:270–6.

    PubMed  Google Scholar 

  119. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry. 2003;74:720–4.

    PubMed  CAS  Google Scholar 

  120. Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C. Islington study of dementia subtypes in the community. Br J Psychiatry. 2002;180:270–6.

    PubMed  Google Scholar 

  121. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841.

    PubMed  CAS  Google Scholar 

  122. Lockhart PJ, Kachergus J, Lincoln S, Hulihan M, Bisceglio G, Thomas N, et al. Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease. J Mol Neurosci. 2004;24:337–42.

    PubMed  CAS  Google Scholar 

  123. Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67:908–10.

    PubMed  CAS  Google Scholar 

  124. Mata IF, Samii A, Schneer SH, Roberts JW, Griffith A, Leis BC, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol. 2008;65:379–82.

    PubMed  Google Scholar 

  125. Aarsland D, Rongve A, Nore SP, Skogseth R, Skulstad S, Ehrt U, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord. 2008;26:445–52.

    PubMed  Google Scholar 

  126. Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62:181–7.

    PubMed  CAS  Google Scholar 

  127. Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2001;70:157–64.

    PubMed  CAS  Google Scholar 

  128. Crowell TA, Luis CA, Cox DE, Mullan M. Neuropsychological comparison of Alzheimer’s disease and dementia with lewy bodies. Dement Geriatr Cogn Disord. 2007;23:120–5.

    PubMed  Google Scholar 

  129. Mori E, Shimomura T, Fujimori M, Hirono N, Imamura T, Hashimoto M, et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol. 2000;57:489–93.

    PubMed  CAS  Google Scholar 

  130. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia? Brain. 2006;129:729–35.

    PubMed  Google Scholar 

  131. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969–78.

    PubMed  CAS  Google Scholar 

  132. McKeith IG, Ballard CG, Perry RH, Ince PG, O’Brien JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050–8.

    PubMed  CAS  Google Scholar 

  133. Ferman TJ, Smith GE, Boeve BF, Graff-Radford NR, Lucas JA, Knopman DS, et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer’s disease. Clin Neuropsychol. 2006;20:623–36.

    PubMed  Google Scholar 

  134. McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123 I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.

    PubMed  Google Scholar 

  135. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73:134–40.

    PubMed  CAS  Google Scholar 

  136. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358–65.

    PubMed  CAS  Google Scholar 

  137. Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001;71:583–8.

    PubMed  CAS  Google Scholar 

  138. Estorch M, Camacho V, Paredes P, Rivera E, Rodriguez-Revuelto A, Flotats A, et al. Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging. 2008;35:1636–41.

    PubMed  Google Scholar 

  139. Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, et al. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2006;33:248–53.

    PubMed  Google Scholar 

  140. Colloby SJ, Fenwick JD, Williams ED, Paling SM, Lobotesis K, Ballard C, et al. A comparison of (99 m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging. 2002;29:615–22.

    PubMed  Google Scholar 

  141. Kemp PM, Hoffmann SA, Tossici-Bolt L, Fleming JS, Holmes C. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nucl Med Commun. 2007;28:451–6.

    PubMed  Google Scholar 

  142. Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47:462–6.

    PubMed  CAS  Google Scholar 

  143. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Differentiation of Alzheimer’s disease from dementia with Lewy bodies utilizing positron emission tomography with [18 F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol. 2005;191 Suppl 1:S95–103.

    PubMed  CAS  Google Scholar 

  144. Ishii K, Soma T, Kono AK, Sofue K, Miyamoto N, Yoshikawa T, et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer’s disease. J Nucl Med. 2007;48:704–11.

    PubMed  Google Scholar 

  145. Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med. 2004;18:453–61.

    PubMed  Google Scholar 

  146. Novellino F, Bagnato A, Salsone M, Cascini GL, Nicoletti G, Arabia G, et al. Myocardial (123)I-MIBG scintigraphy for differentiation of Lewy Bodies Disease from FTD. Neurobiol Aging. 2009;31(11):1903–11.

    PubMed  Google Scholar 

  147. Middelkoop HA, van der Flier WM, Burton EJ, Lloyd AJ, Paling S, Barber R, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology. 2001;57:2117–20.

    PubMed  CAS  Google Scholar 

  148. Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O’Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease: an MRI study. Neurology. 2003;61:1191–5.

    PubMed  CAS  Google Scholar 

  149. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain. 2007;130:708–19.

    PubMed  Google Scholar 

  150. Briel RC, McKeith IG, Barker WA, Hewitt Y, Perry RH, Ince PG, et al. EEG findings in dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1999;66:401–3.

    PubMed  CAS  Google Scholar 

  151. Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology. 1990;40:1523–8.

    PubMed  CAS  Google Scholar 

  152. Doran M, Larner AJ. EEG findings in dementia with Lewy bodies causing diagnostic confusion with sporadic Creutzfeldt-Jakob disease. Eur J Neurol. 2004;11:838–41.

    PubMed  CAS  Google Scholar 

  153. Barber PA, Varma AR, Lloyd JJ, Haworth B, Snowden JS, Neary D. The electroencephalogram in dementia with Lewy bodies. Acta Neurol Scand. 2000;101:53–6.

    PubMed  CAS  Google Scholar 

  154. Londos E, Passant U, Brun A, Rosen I, Risberg J, Gustafson L. Regional cerebral blood flow and EEG in clinically diagnosed dementia with Lewy bodies and Alzheimer’s disease. Arch Gerontol Geriatr. 2003;36:231–45.

    PubMed  Google Scholar 

  155. Andersson M, Hansson O, Minthon L, Rosen I, Londos E. Electroencephalogram variability in dementia with lewy bodies, Alzheimer’s disease and controls. Dement Geriatr Cogn Disord. 2008;26:284–90.

    PubMed  CAS  Google Scholar 

  156. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain. 2008;131:690–705.

    PubMed  Google Scholar 

  157. Roks G, Korf ES, van der Flier WM, Scheltens P, Stam CJ. The use of EEG in the diagnosis of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2008;79:377–80.

    PubMed  CAS  Google Scholar 

  158. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, et al. CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies. J Neural Transm. 2006;113:1771–8.

    PubMed  CAS  Google Scholar 

  159. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2005;19:164–70.

    PubMed  CAS  Google Scholar 

  160. Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci. 2007;260:33–7.

    PubMed  Google Scholar 

  161. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213:315–25.

    PubMed  CAS  Google Scholar 

  162. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, et al. CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain. 2006;129:1177–87.

    PubMed  Google Scholar 

  163. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders – a marker of synapse loss? Neurosci Lett. 2009;450:332–5.

    PubMed  Google Scholar 

  164. Gwinn-Hardy K, Singleton AA. Familial Lewy body diseases. J Geriatr Psychiatry Neurol. 2002;15:217–23.

    PubMed  Google Scholar 

  165. Tsuang DW, DiGiacomo L, Bird TD. Familial occurrence of dementia with Lewy bodies. Am J Geriatr Psychiatry. 2004;12:179–88.

    PubMed  Google Scholar 

  166. Johnson J, Hague SM, Hanson M, Gibson A, Wilson KE, Evans EW, et al. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology. 2004;63:554–6.

    PubMed  CAS  Google Scholar 

  167. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:549–53.

    PubMed  CAS  Google Scholar 

  168. Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356–63.

    PubMed  CAS  Google Scholar 

  169. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13:67–73.

    PubMed  CAS  Google Scholar 

  170. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205–14.

    PubMed  Google Scholar 

  171. Allen RL, Walker Z, D’Ath PJ, Katona CL. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet. 1995;346:185.

    PubMed  CAS  Google Scholar 

  172. McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet. 1995;346:699.

    PubMed  CAS  Google Scholar 

  173. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17:165–71.

    PubMed  CAS  Google Scholar 

  174. Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 1998;10:227–9.

    PubMed  CAS  Google Scholar 

  175. Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci. 1993;5:206–8.

    PubMed  CAS  Google Scholar 

  176. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology. 2004;63:376–8.

    PubMed  CAS  Google Scholar 

  177. Molloy S, McKeith IG, O’Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76:1200–3.

    PubMed  CAS  Google Scholar 

  178. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–6.

    PubMed  CAS  Google Scholar 

  179. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13:183–92.

    PubMed  CAS  Google Scholar 

  180. Simard M, van Reekum R. The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 2004;16:409–25.

    PubMed  CAS  Google Scholar 

  181. Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord. 2007;23:401–5.

    PubMed  CAS  Google Scholar 

  182. Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry Clin Neurosci. 2006;60:190–5.

    PubMed  Google Scholar 

  183. Ballard C, Lane R, Barone P, Ferrara R, Tekin S. Cardiac safety of rivastigmine in Lewy body and Parkinson’s disease dementias. Int J Clin Pract. 2006;60:639–45.

    PubMed  CAS  Google Scholar 

  184. Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs. Alzheimer disease. Neurology. 2006;67:1935–41.

    PubMed  Google Scholar 

  185. Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis. 2007;4:428–30.

    PubMed  Google Scholar 

  186. Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology. 1998;51:351–7.

    PubMed  CAS  Google Scholar 

  187. Hebert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF. Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke. 2000;31:1487–93.

    PubMed  CAS  Google Scholar 

  188. Andreasen N, Blennow K, Sjodin C, Winblad B, Svardsudd K. Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Pitea Dementia Project. Neuroepidemiology. 1999;18:144–55.

    PubMed  CAS  Google Scholar 

  189. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007;257:80–7.

    PubMed  CAS  Google Scholar 

  190. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197–204.

    PubMed  Google Scholar 

  191. Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord. 2006;20:93–100.

    PubMed  Google Scholar 

  192. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord. 2002;14:77–83.

    PubMed  Google Scholar 

  193. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004;63:1181–6.

    PubMed  CAS  Google Scholar 

  194. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49–55.

    PubMed  CAS  Google Scholar 

  195. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002;58:1175–81.

    PubMed  CAS  Google Scholar 

  196. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995;45:1161–8.

    PubMed  CAS  Google Scholar 

  197. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–60.

    PubMed  CAS  Google Scholar 

  198. Gold G, Bouras C, Canuto A, Bergallo MF, Herrmann FR, Hof PR, et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry. 2002;159:82–7.

    PubMed  Google Scholar 

  199. Reed BR, Mungas DM, Kramer JH, Ellis W, Vinters HV, Zarow C, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer’s disease and cerebrovascular disease. Brain. 2007;130:731–9.

    PubMed  Google Scholar 

  200. Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JC, Wen W, et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology. 2004;62:912–9.

    PubMed  CAS  Google Scholar 

  201. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer’s disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004;75:61–71.

    PubMed  CAS  Google Scholar 

  202. Longstreth Jr WT, Arnold AM, Beauchamp Jr NJ, Manolio TA, Lefkowitz D, Jungreis C, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke. 2005;36:56–61.

    PubMed  Google Scholar 

  203. Price CC, Jefferson AL, Merino JG, Heilman KM, Libon DJ. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data. Neurology. 2005;65:376–82.

    PubMed  CAS  Google Scholar 

  204. Hunt AL, Orrison WW, Yeo RA, Haaland KY, Rhyne RL, Garry PJ, et al. Clinical significance of MRI white matter lesions in the elderly. Neurology. 1989;39:1470–4.

    PubMed  CAS  Google Scholar 

  205. Mendez MF, Ottowitz W, Brown CV, Cummings JL, Perryman KM, Mandelkern MA. Dementia with leukoaraiosis: clinical differentiation by temporoparietal hypometabolism on (18)FDG-PET imaging. Dement Geriatr Cogn Disord. 1999;10:518–25.

    PubMed  CAS  Google Scholar 

  206. Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC. 18FDG PET in vascular dementia: differentiation from Alzheimer’s disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab. 2006;26:1213–21.

    PubMed  CAS  Google Scholar 

  207. Nagata K, Maruya H, Yuya H, Terashi H, Mito Y, Kato H, et al. Can PET data differentiate Alzheimer’s disease from vascular dementia? Ann NY Acad Sci. 2000;903:252–61.

    PubMed  CAS  Google Scholar 

  208. de Jong D, Jansen RW, Kremer BP, Verbeek MM. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci. 2006;61:755–8.

    PubMed  Google Scholar 

  209. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, Zalonis I, et al. CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol. 2009;16: 205–11.

    PubMed  CAS  Google Scholar 

  210. Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, Koch G, et al. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci. 2005;237:83–8.

    PubMed  Google Scholar 

  211. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782–92.

    PubMed  CAS  Google Scholar 

  212. Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7:310–8.

    PubMed  CAS  Google Scholar 

  213. in’t Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001;22:407–412.

    Google Scholar 

  214. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev. 2006:CD004034.

    Google Scholar 

  215. Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.

    PubMed  CAS  Google Scholar 

  216. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62:1047–51.

    PubMed  Google Scholar 

  217. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.

    PubMed  CAS  Google Scholar 

  218. ten Dam VH, van den Heuvel DM, van Buchem MA, Westendorp RG, Bollen EL, Ford I, et al. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology. 2005;64:1807–9.

    PubMed  Google Scholar 

  219. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology. 2008;70:17–24.

    PubMed  CAS  Google Scholar 

  220. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989;37:549–55.

    PubMed  CAS  Google Scholar 

  221. Williams PS, Rands G, Orrel M, Spector A. Aspirin for vascular dementia. Cochrane Database Syst Rev. 2000:CD001296.

    Google Scholar 

  222. Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W. Survival following dementia onset: Alzheimer’s disease and vascular dementia. J Neurol Sci. 2005;229–230:43–9.

    PubMed  Google Scholar 

  223. Knopman DS, Rocca WA, Cha RH, Edland SD, Kokmen E. Survival study of vascular dementia in Rochester, Minnesota. Arch Neurol. 2003;60:85–90.

    PubMed  Google Scholar 

  224. Wolfson C, Wolfson DB, Asgharian M, M’Lan CE, Ostbye T, Rockwood K, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111–6.

    PubMed  CAS  Google Scholar 

  225. Brunnstrom HR, Englund EM. Cause of death in patients with dementia disorders. Eur J Neurol. 2009;16(4):488–92.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Neurological Sciences, University of Western Ontario, 268 Grosvenor Street, Suite D0-224, London, ON, Canada, N6A 4V2

    Elizabeth Finger MD

  2. Division of Cognitive and Behavioral Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Kirk R. Daffner MD

  3. Neurology, Harvard Medical School, Boston, MA, USA

    Kirk R. Daffner MD

Authors
  1. Elizabeth Finger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kirk R. Daffner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Finger MD .

Editor information

Editors and Affiliations

  1. London Health Sciences Centre, Dept. Clinical Neurosciences, University of Western Ontario, Windermere Road 339, London, N6A 5A5, Ontario, Canada

    Jorge G. Burneo

  2. , Neurology, Mayo Clinic Hospital, E. Mayo Blvd. 5777, Phoenix, 85054, Arizona, USA

    Bart M. Demaerschalk

  3. London Health Sciences Centre, Dept. Clinical Neurosciences, University of Western Ontario, Windermere Road 339, London, N6A 5A5, Ontario, Canada

    Mary E. Jenkins

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Finger, E., Daffner, K.R. (2012). Cognitive and Behavioral Neurology. In: Burneo, J., Demaerschalk, B., Jenkins, M. (eds) Neurology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-88555-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-88555-1_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-88554-4

  • Online ISBN: 978-0-387-88555-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation